Aldevron Breakthrough Blog: mRNA

Webinar: How a Sponsored CMC Platform Accelerates mRNA Projects into the Clinic

Streamlining development, ensuring quality and safety

When discussing mRNA development, the complexity across a variety of modalities can give pause to how the projects should be approached and developed. With that in mind, Jon Cooper, Ph.D., Senior Director of RNA Sciences & Analytical Development recently presented, How a Sponsored CMC Platform Accelerates mRNA Projects into the Clinic, in this webinar and recently at the mRNA Analytical Development Summit in Boston, to provide an outline of an effective development process.

Read More

Capacity versus capability

What do they mean for you?

Capacity: The total amount that can be contained or produced
Capability: The ability to do something
*As defined by the Cambridge Dictionary

One of the issues I’ve heard raised in our industry is about how we define capacity and capability. As you can see from the definitions above, these are two very different items. But what do these two terms mean with respect to the manufacture of mRNA drug substance and/or drug product?

Read More

When Preparation Meets Opportunity

mRNA’s rise amidst the COVID pandemic

The introduction of mRNA vaccines by Pfizer and Moderna for COVID-19 took much of the world by surprise. But for Katalin Karikó, Pieter Cullis, and Drew Weissman, among others, it was merely the culmination of decades of research and development. Implementing a novel modality during such a public health crisis took confidence, determination, and the hard work of millions of people. It didn’t happen overnight.

Read More

Four Major Steps Involved in mRNA Manufacturing

From potential to solution

For more than two decades, in vitro transcribed (IVT) messenger RNA (mRNA) has been considered for its potential to address unmet medical needs and to transform the development and manufacture of medicines. This potential was suddenly realized by the unprecedented response to Covid 19, ushering in a new era in the application of mRNA technologies to solve challenging health problems.

Read More

RNA is Only One Ingredient in RNA Development

Defining paths and building relationships

While research into RNA, including mRNA and related derivatives, has been ongoing for almost 50 years, it’s taken the COVID-19 pandemic to accelerate the development of vaccines using this technology. mRNA provides an incredible opportunity to develop new treatments for viral based, genetically driven, or cancerous diseases.

Read More

Structured DNA Repeats

A plasmid replication challenge

For decades, the cell and gene therapy industry has been using the same plasmid technology in vaccination, cell and gene therapy, and as a raw material in viral vector and RNA production. In some cases, that technology isn’t a good fit for the processes where it’s being used. Now, with the growing popularity of Nanoplasmid™ vectors, that is starting to change.

Read More

Building an mRNA Ecosystem

Capacity is only part of the solution

During conferences and seminars this year, there has been one particular topic that has come to the fore regarding mRNA production – capacity. Most of the concern comes from the impression that there isn’t enough capacity to meet market demand.

Read More

A Three-Step RNA Progression

An outlook for mRNA, saRNA and Circular RNA

When mRNA vaccines began to roll out in late 2020 to fight the COVID pandemic, it was the first large-scale use of the molecule after years of research. But the success of those vaccines was only the beginning of new opportunities for the RNA field.

Read More